Last reviewed · How we verify

MEBO Wound Ointment (MEBO)

Skingenix, Inc. · Phase 3 active Small molecule

MEBO Wound Ointment promotes wound healing by creating a moist healing environment and stimulating tissue regeneration and epithelialization.

MEBO Wound Ointment promotes wound healing by creating a moist healing environment and stimulating tissue regeneration and epithelialization. Used for Burn wounds, Chronic wounds, Wound healing acceleration.

At a glance

Generic nameMEBO Wound Ointment (MEBO)
Also known asMEBO
SponsorSkingenix, Inc.
Drug classTopical wound healing agent
ModalitySmall molecule
Therapeutic areaDermatology / Wound Care
PhasePhase 3

Mechanism of action

MEBO is a topical ointment formulation containing a blend of oils and botanical extracts designed to maintain optimal moisture at the wound site while promoting angiogenesis and collagen deposition. The formulation is intended to accelerate the natural healing process by supporting the proliferative and remodeling phases of wound repair, particularly in burn wounds and chronic wounds.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: